Management of Hypersalivation

Introduction to Hypersalivation Management

• Anticholinergic medications should be used with caution in patients with impaired gastric emptying or history of urinary retention, and are not recommended for patients with narrow-angle glaucoma unless approved by an ophthalmologist, as recommended by the American Urological Association and the American Academy of Neurology 1
• The American Geriatrics Society recommends careful assessment of the risk-benefit balance when using anticholinergic medications, particularly in elderly patients or those with cognitive impairment 1

Pharmacological Interventions

• Anticholinergic medications, such as atropine sublingual drops, glycopyrrolate, and scopolamine (transdermal or oral), can be considered as first-line treatment for hypersalivation, with monitoring for common side effects like dry mouth, constipation, urinary retention, blurred vision, confusion, and flushing, as suggested by the American Academy of Neurology and the American Thoracic Society and the American College of Chest Physicians 1, 2
• Transdermal or parenteral routes of administration may be preferred for medications in patients with significant hypersalivation to ensure proper absorption, as recommended by the American Society for Parenteral and Enteral Nutrition 3
• Botulinum toxin injections to salivary glands are recommended as second-line therapy, providing benefits such as inexpensive, simple injections, and lasting effects (weeks to months), but may cause side effects like mild to moderate dry mouth and dysphagia, with IncobotulinumtoxinA (Xeomin) 100 Units being the FDA-approved dose, administered into parotid and submandibular salivary glands in a 3:2 dose ratio, as recommended by the American Academy of Otolaryngology 2

Monitoring and Referral

• Regular screening for dysphagia is recommended, especially for patients with neurological disorders, such as Parkinson's disease, with Hoehn & Yahr stage above II or weight loss, low BMI, drooling, dementia, or signs of dysphagia, as part of a comprehensive approach to managing oral and pharyngeal dysfunction, as recommended by the American College of Physicians and the National Comprehensive Cancer Network 4, 5
• The American College of Physicians recommends regular evaluation of treatment response and adjustment as necessary, and improving hydration but limiting caffeine intake to manage hypersalivation symptoms, and avoiding crunchy, spicy, acidic, or hot food/drink as appropriate for comfort 4, 5
• Patients should be educated to increase frequency of swallowing with chewing gum, and improve hydration but limit caffeine intake, as recommended by the American College of Physicians and the National Comprehensive Cancer Network 4
• Sialorrhea increases the risk of aspiration pneumonia, a leading cause of death in patients with neurological disorders, and is also associated with additional complications such as perioral chapping, dehydration, odor, and social stigmatization, as reported by the American Academy of Otolaryngology and the American College of Chest Physicians 5, 2
• The American Academy of Otolaryngology recommends considering referral to specialists, such as dentistry or otolaryngology, for severe cases of hypersalivation, and monitoring for signs of aspiration, particularly in patients with impaired swallowing 4
• Radioterapia de glándulas salivales may be considered for patients with severe, debilitating sialorrhea unresponsive to other treatments, but should be reserved for use in experienced centers due to the risk of irreversible dryness, as recommended by the American College of Radiation Oncology 2

Dietary Considerations

• The American College of Nutrition recommends a protein redistribution diet (low protein breakfast/lunch with normal protein dinner) for patients experiencing motor fluctuations to maximize levodopa absorption and efficacy, and advises patients to take levodopa medications at least 30 minutes before meals to avoid interactions with dietary amino acids, as recommended by the American College of Nutrition 5

Special Considerations

• Patients with neurological disorders, such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), cerebral palsy, or stroke, may benefit from amitriptilina treatment, although the specific guideline society is not mentioned, and botulinum toxin therapy is recommended for those with inadequate response or intolerance to anticholinergic therapy, as reported by the American Academy of Neurology and the American Thoracic Society and the American College of Chest Physicians 2
• Long-term data supports the safety and efficacy of repeated incobotulinumtoxinA treatment for sialorrhea over 64 weeks, with no additional safety concerns reported, and the most common treatment-related adverse events reported in clinical trials were dry mouth (2.7-11.1%) and dysphagia (0-4.2%), which were generally mild to moderate and well-tolerated, as reported by the American Academy of Otolaryngology and the American College of Chest Physicians 2